Why the study?
Does echocardiographic evidence of mitral valve prolapse influence treatment decisions for antibiotic prophylaxis and beta-blocker therapy in outpatients suspected of MVP?
Does echocardiographic evidence of mitral valve prolapse influence treatment decisions for antibiotic prophylaxis and beta-blocker therapy in outpatients suspected of MVP?
In outpatients suspected of MVP, echocardiographic results primarily drive decisions for endocarditis prophylaxis rather than symptom management with beta-blockers.
Echocardiography drives prophylaxis decisions more than symptoms drive beta-blocker use in suspected MVP; leaves open optimal criteria pending prospective validation.
Although echocardiography is frequently ordered in ambulatory settings for patients suspected of mitral valve prolapse (MVP), its impact on their subsequent management is unknown. We studied the relationship between the results of echocardiography for outpatients suspected of MVP, and two frequent medical decisions: treatment with beta blockers and the recommendation of antibiotic prophylaxis to prevent bacterial endocarditis. A medical record audit was performed on 274 outpatients referred to a university medical center echocardiography laboratory to rule out MVP. Although echocardiographic evidence for MVP significantly influenced the decision to recommend antibiotic prophylaxis (P less than 0.001), symptoms were more likely to be used as indications for beta-blocker therapy in patients suspected of the condition. We conclude that echocardiographic results are used for recommending antibiotic prophylaxis to outpatients suspected of MVP, but not for beta-blocker therapy.
No takes yet. Share an insight, caveat, or question.
Retchin et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: